| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 267 | 2024 | 6858 | 13.050 |
Why?
|
| Drug Resistance, Viral | 110 | 2023 | 861 | 9.870 |
Why?
|
| Anti-HIV Agents | 187 | 2024 | 4524 | 8.350 |
Why?
|
| HIV Infections | 304 | 2024 | 17342 | 8.160 |
Why?
|
| Reverse Transcriptase Inhibitors | 64 | 2023 | 621 | 5.360 |
Why?
|
| HIV Reverse Transcriptase | 33 | 2020 | 212 | 4.440 |
Why?
|
| HIV Fusion Inhibitors | 24 | 2013 | 82 | 3.910 |
Why?
|
| Viral Load | 104 | 2023 | 3325 | 3.630 |
Why?
|
| Lamivudine | 39 | 2021 | 366 | 3.470 |
Why?
|
| Zidovudine | 47 | 2021 | 624 | 2.920 |
Why?
|
| RNA, Viral | 106 | 2024 | 2838 | 2.680 |
Why?
|
| HIV Integrase Inhibitors | 11 | 2024 | 165 | 2.600 |
Why?
|
| Anti-Retroviral Agents | 35 | 2023 | 1783 | 2.540 |
Why?
|
| Antiretroviral Therapy, Highly Active | 45 | 2018 | 1894 | 2.530 |
Why?
|
| Acquired Immunodeficiency Syndrome | 43 | 2023 | 2197 | 2.420 |
Why?
|
| Receptors, CCR5 | 15 | 2016 | 486 | 1.990 |
Why?
|
| Viremia | 20 | 2023 | 706 | 1.960 |
Why?
|
| HIV Envelope Protein gp41 | 17 | 2012 | 303 | 1.830 |
Why?
|
| CD4 Lymphocyte Count | 83 | 2023 | 2567 | 1.710 |
Why?
|
| HIV Integrase | 4 | 2023 | 121 | 1.660 |
Why?
|
| Benzoxazines | 22 | 2020 | 316 | 1.580 |
Why?
|
| Virus Replication | 26 | 2023 | 2427 | 1.540 |
Why?
|
| Piperazines | 23 | 2024 | 2521 | 1.410 |
Why?
|
| HIV | 24 | 2021 | 1580 | 1.380 |
Why?
|
| Drug Resistance, Multiple, Viral | 11 | 2008 | 52 | 1.350 |
Why?
|
| HIV Seropositivity | 9 | 2023 | 959 | 1.310 |
Why?
|
| Pyrrolidinones | 8 | 2014 | 116 | 1.260 |
Why?
|
| Receptors, HIV | 6 | 2016 | 158 | 1.250 |
Why?
|
| Mutation | 76 | 2023 | 30015 | 1.200 |
Why?
|
| HIV Protease Inhibitors | 25 | 2020 | 432 | 1.180 |
Why?
|
| Ritonavir | 24 | 2022 | 329 | 1.140 |
Why?
|
| Virology | 4 | 2010 | 75 | 1.100 |
Why?
|
| DNA, Viral | 24 | 2024 | 2194 | 1.090 |
Why?
|
| Pyrimidines | 15 | 2012 | 3027 | 1.030 |
Why?
|
| Virus Internalization | 6 | 2013 | 497 | 1.000 |
Why?
|
| AIDS Vaccines | 11 | 2023 | 896 | 0.980 |
Why?
|
| Peptide Fragments | 21 | 2016 | 5109 | 0.950 |
Why?
|
| CD4-Positive T-Lymphocytes | 33 | 2024 | 4365 | 0.950 |
Why?
|
| Adenine | 10 | 2021 | 985 | 0.860 |
Why?
|
| Treatment Failure | 27 | 2021 | 2635 | 0.840 |
Why?
|
| Alkynes | 22 | 2020 | 320 | 0.790 |
Why?
|
| Cyclopropanes | 22 | 2020 | 432 | 0.760 |
Why?
|
| Humans | 386 | 2024 | 760740 | 0.760 |
Why?
|
| Drug Resistance, Microbial | 24 | 2004 | 825 | 0.740 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 7 | 2024 | 287 | 0.740 |
Why?
|
| Cyclohexanes | 8 | 2013 | 152 | 0.730 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 6 | 2016 | 369 | 0.720 |
Why?
|
| Viral Tropism | 8 | 2016 | 102 | 0.710 |
Why?
|
| Receptors, CXCR4 | 8 | 2016 | 727 | 0.710 |
Why?
|
| Oxazines | 12 | 2024 | 349 | 0.700 |
Why?
|
| Drug Therapy, Combination | 56 | 2018 | 6305 | 0.650 |
Why?
|
| Pyridones | 11 | 2024 | 808 | 0.630 |
Why?
|
| Salvage Therapy | 5 | 2006 | 1263 | 0.630 |
Why?
|
| Polymerase Chain Reaction | 17 | 2020 | 6074 | 0.620 |
Why?
|
| Lymphocyte Activation | 17 | 2020 | 5463 | 0.620 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2004 | 629 | 0.620 |
Why?
|
| Proviruses | 9 | 2024 | 313 | 0.600 |
Why?
|
| Microbial Sensitivity Tests | 19 | 2016 | 1936 | 0.600 |
Why?
|
| Didanosine | 11 | 2010 | 151 | 0.570 |
Why?
|
| Stavudine | 7 | 2012 | 85 | 0.560 |
Why?
|
| Clinical Trials as Topic | 19 | 2016 | 7995 | 0.550 |
Why?
|
| HIV Protease | 11 | 2009 | 97 | 0.550 |
Why?
|
| DNA, Circular | 2 | 2015 | 96 | 0.530 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2014 | 465 | 0.530 |
Why?
|
| Dideoxynucleosides | 10 | 2017 | 135 | 0.520 |
Why?
|
| Triazoles | 8 | 2013 | 903 | 0.500 |
Why?
|
| Genotype | 39 | 2021 | 12977 | 0.490 |
Why?
|
| Medication Adherence | 6 | 2014 | 2175 | 0.480 |
Why?
|
| Genes, env | 4 | 2012 | 95 | 0.460 |
Why?
|
| South Africa | 17 | 2023 | 1843 | 0.460 |
Why?
|
| HIV Envelope Protein gp120 | 10 | 2016 | 914 | 0.460 |
Why?
|
| Ethics, Research | 2 | 2006 | 176 | 0.450 |
Why?
|
| Rectum | 2 | 2018 | 891 | 0.440 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2024 | 330 | 0.440 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2023 | 1834 | 0.430 |
Why?
|
| Sequence Analysis, DNA | 13 | 2017 | 4739 | 0.420 |
Why?
|
| Virus Latency | 5 | 2024 | 354 | 0.420 |
Why?
|
| Antiviral Agents | 14 | 2022 | 3037 | 0.420 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2012 | 85 | 0.410 |
Why?
|
| Drugs, Investigational | 3 | 2012 | 212 | 0.410 |
Why?
|
| HIV Antibodies | 8 | 2024 | 1302 | 0.410 |
Why?
|
| Pyridazines | 2 | 2011 | 201 | 0.400 |
Why?
|
| Botswana | 10 | 2024 | 1049 | 0.400 |
Why?
|
| Herpesvirus 4, Human | 3 | 2017 | 1077 | 0.390 |
Why?
|
| Lab-On-A-Chip Devices | 6 | 2018 | 432 | 0.390 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2018 | 5671 | 0.390 |
Why?
|
| Genes, pol | 4 | 2007 | 52 | 0.390 |
Why?
|
| Molecular Sequence Data | 26 | 2014 | 17630 | 0.390 |
Why?
|
| Adult | 132 | 2024 | 220995 | 0.390 |
Why?
|
| Microfluidic Analytical Techniques | 7 | 2017 | 799 | 0.380 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 5 | 2023 | 206 | 0.380 |
Why?
|
| Biosensing Techniques | 5 | 2015 | 647 | 0.370 |
Why?
|
| Amino Acid Substitution | 6 | 2023 | 1739 | 0.370 |
Why?
|
| Infectious Disease Transmission, Vertical | 9 | 2021 | 1351 | 0.370 |
Why?
|
| Nevirapine | 10 | 2023 | 273 | 0.360 |
Why?
|
| Mutation, Missense | 7 | 2011 | 2570 | 0.360 |
Why?
|
| Vaccines, DNA | 3 | 2023 | 283 | 0.360 |
Why?
|
| Withholding Treatment | 7 | 2019 | 615 | 0.350 |
Why?
|
| Stem Cell Transplantation | 3 | 2018 | 1600 | 0.330 |
Why?
|
| RNA-Directed DNA Polymerase | 6 | 2009 | 225 | 0.330 |
Why?
|
| Neutropenia | 3 | 2000 | 885 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 4569 | 0.320 |
Why?
|
| AIDS-Related Opportunistic Infections | 5 | 2010 | 662 | 0.310 |
Why?
|
| Gene Products, gag | 4 | 2010 | 312 | 0.300 |
Why?
|
| Indinavir | 5 | 2006 | 73 | 0.300 |
Why?
|
| Patient Selection | 7 | 2023 | 4237 | 0.300 |
Why?
|
| Male | 128 | 2024 | 360402 | 0.300 |
Why?
|
| Plasma | 6 | 2016 | 586 | 0.290 |
Why?
|
| Point-of-Care Systems | 8 | 2018 | 1213 | 0.280 |
Why?
|
| Female | 128 | 2024 | 392203 | 0.270 |
Why?
|
| Cytidine Triphosphate | 2 | 2007 | 17 | 0.270 |
Why?
|
| Phylogeny | 10 | 2023 | 2805 | 0.270 |
Why?
|
| CD8-Positive T-Lymphocytes | 13 | 2024 | 4570 | 0.270 |
Why?
|
| Receptors, Virus | 2 | 2009 | 639 | 0.260 |
Why?
|
| Metal Nanoparticles | 3 | 2020 | 399 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2001 | 1779 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2004 | 225 | 0.250 |
Why?
|
| Virus Integration | 2 | 2018 | 304 | 0.250 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 4802 | 0.250 |
Why?
|
| Thymidine | 1 | 2005 | 297 | 0.250 |
Why?
|
| Receptors, Chemokine | 2 | 2015 | 652 | 0.250 |
Why?
|
| Amino Acid Sequence | 12 | 2016 | 13442 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 9171 | 0.240 |
Why?
|
| DNA Primers | 8 | 2024 | 2817 | 0.240 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2003 | 239 | 0.240 |
Why?
|
| Herpesvirus 8, Human | 2 | 2018 | 255 | 0.240 |
Why?
|
| Point Mutation | 3 | 2007 | 1595 | 0.240 |
Why?
|
| Interleukin-12 | 2 | 1998 | 577 | 0.240 |
Why?
|
| Recombination, Genetic | 3 | 2008 | 1519 | 0.230 |
Why?
|
| Interleukin-2 | 2 | 2009 | 1888 | 0.230 |
Why?
|
| Sulfonamides | 7 | 2014 | 1977 | 0.230 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2015 | 614 | 0.220 |
Why?
|
| Codon | 9 | 2007 | 600 | 0.220 |
Why?
|
| RNA Stability | 3 | 2017 | 320 | 0.220 |
Why?
|
| Electricity | 2 | 2015 | 175 | 0.220 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 858 | 0.220 |
Why?
|
| Platinum | 3 | 2020 | 220 | 0.210 |
Why?
|
| Lymphoma | 2 | 2009 | 1899 | 0.210 |
Why?
|
| Sensitivity and Specificity | 15 | 2020 | 14649 | 0.210 |
Why?
|
| Middle Aged | 72 | 2024 | 220603 | 0.210 |
Why?
|
| United Nations | 1 | 2003 | 149 | 0.210 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2004 | 137 | 0.210 |
Why?
|
| Patient Compliance | 9 | 2012 | 2688 | 0.210 |
Why?
|
| Treatment Outcome | 35 | 2023 | 64572 | 0.210 |
Why?
|
| Nelfinavir | 5 | 2017 | 68 | 0.210 |
Why?
|
| Cell Line | 12 | 2016 | 15577 | 0.210 |
Why?
|
| Disease Reservoirs | 2 | 2019 | 121 | 0.200 |
Why?
|
| T-Lymphocytes | 11 | 2020 | 10175 | 0.200 |
Why?
|
| Internationality | 2 | 2021 | 1000 | 0.200 |
Why?
|
| Nanotechnology | 3 | 2013 | 713 | 0.200 |
Why?
|
| Phenotype | 17 | 2019 | 16572 | 0.190 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2024 | 774 | 0.190 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 39 | 0.190 |
Why?
|
| Filgrastim | 5 | 2004 | 132 | 0.190 |
Why?
|
| Chemoprevention | 2 | 2014 | 325 | 0.190 |
Why?
|
| Antibodies, Immobilized | 2 | 2012 | 23 | 0.190 |
Why?
|
| Delavirdine | 1 | 2000 | 7 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2016 | 3426 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 10203 | 0.180 |
Why?
|
| Lymphocytes | 7 | 2009 | 2604 | 0.180 |
Why?
|
| Gene Products, env | 4 | 1996 | 250 | 0.180 |
Why?
|
| Placebos | 8 | 2023 | 1667 | 0.180 |
Why?
|
| Drug Therapy | 3 | 2020 | 503 | 0.170 |
Why?
|
| Double-Blind Method | 21 | 2023 | 12333 | 0.170 |
Why?
|
| Drug Administration Schedule | 10 | 2018 | 4845 | 0.170 |
Why?
|
| HIV Long-Term Survivors | 2 | 2018 | 121 | 0.170 |
Why?
|
| Integrase Inhibitors | 2 | 2017 | 12 | 0.170 |
Why?
|
| Interferon-alpha | 1 | 2024 | 901 | 0.170 |
Why?
|
| Nanostructures | 2 | 2015 | 551 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 285 | 0.170 |
Why?
|
| Evolution, Molecular | 7 | 2016 | 1880 | 0.170 |
Why?
|
| Pharmacogenetics | 4 | 2011 | 675 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 3 | 2024 | 1936 | 0.160 |
Why?
|
| Rural Health | 1 | 2020 | 296 | 0.160 |
Why?
|
| Models, Biological | 4 | 2010 | 9461 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2021 | 1661 | 0.160 |
Why?
|
| RNA Splice Sites | 1 | 2020 | 210 | 0.160 |
Why?
|
| Photometry | 2 | 2009 | 57 | 0.160 |
Why?
|
| Lymphopenia | 1 | 2021 | 281 | 0.160 |
Why?
|
| Flow Cytometry | 12 | 2017 | 5863 | 0.160 |
Why?
|
| Endpoint Determination | 2 | 2005 | 590 | 0.160 |
Why?
|
| Research Design | 5 | 2013 | 6174 | 0.160 |
Why?
|
| Bacterial Infections | 4 | 2015 | 1389 | 0.160 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2020 | 1493 | 0.160 |
Why?
|
| Statistics, Nonparametric | 4 | 2012 | 2851 | 0.150 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2020 | 366 | 0.150 |
Why?
|
| Developing Countries | 4 | 2007 | 2868 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 2 | 2014 | 561 | 0.150 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2020 | 433 | 0.150 |
Why?
|
| Cell Line, Transformed | 3 | 2009 | 866 | 0.150 |
Why?
|
| Streptococcal Infections | 2 | 1992 | 617 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2005 | 2689 | 0.140 |
Why?
|
| Sirolimus | 1 | 2024 | 1533 | 0.140 |
Why?
|
| Reproducibility of Results | 15 | 2020 | 20077 | 0.140 |
Why?
|
| Pilot Projects | 8 | 2023 | 8619 | 0.140 |
Why?
|
| Recombinant Proteins | 8 | 2004 | 6520 | 0.140 |
Why?
|
| Spermatozoa | 1 | 2021 | 629 | 0.140 |
Why?
|
| Cohort Studies | 17 | 2020 | 41464 | 0.140 |
Why?
|
| Time Factors | 20 | 2016 | 39908 | 0.140 |
Why?
|
| Nanocomposites | 1 | 2017 | 49 | 0.140 |
Why?
|
| Drug Discovery | 2 | 2016 | 1051 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2020 | 2149 | 0.130 |
Why?
|
| Lymphoid Tissue | 1 | 2018 | 445 | 0.130 |
Why?
|
| Lymphocyte Count | 5 | 2018 | 777 | 0.130 |
Why?
|
| Base Sequence | 9 | 2020 | 12420 | 0.130 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1999 | 250 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2003 | 1474 | 0.130 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 2191 | 0.130 |
Why?
|
| Infant, Newborn | 11 | 2023 | 26183 | 0.130 |
Why?
|
| Bacterial Translocation | 1 | 2015 | 73 | 0.130 |
Why?
|
| Research Personnel | 1 | 2020 | 588 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 1692 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2020 | 1088 | 0.120 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 374 | 0.120 |
Why?
|
| Dideoxynucleotides | 2 | 2007 | 13 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 1086 | 0.120 |
Why?
|
| Unsafe Sex | 1 | 2016 | 238 | 0.120 |
Why?
|
| Thymine Nucleotides | 2 | 2007 | 57 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2015 | 3798 | 0.120 |
Why?
|
| Electrodes | 1 | 2017 | 610 | 0.120 |
Why?
|
| Immunity, Innate | 4 | 2022 | 3045 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 3634 | 0.120 |
Why?
|
| Infection Control | 1 | 2021 | 982 | 0.120 |
Why?
|
| Nitriles | 2 | 2011 | 971 | 0.120 |
Why?
|
| Weight Gain | 1 | 2024 | 2349 | 0.120 |
Why?
|
| Drug Approval | 1 | 2021 | 812 | 0.110 |
Why?
|
| Drug Interactions | 5 | 2022 | 1415 | 0.110 |
Why?
|
| Case-Control Studies | 6 | 2021 | 22153 | 0.110 |
Why?
|
| Viral Envelope Proteins | 3 | 2011 | 640 | 0.110 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 3 | 2003 | 138 | 0.110 |
Why?
|
| Patients | 1 | 2020 | 906 | 0.110 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2011 | 202 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2021 | 3356 | 0.110 |
Why?
|
| Tuberculosis | 3 | 2012 | 2015 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 642 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 219 | 0.110 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2014 | 110 | 0.110 |
Why?
|
| Mycobacterium chelonae | 1 | 1993 | 12 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 602 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2012 | 2747 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 748 | 0.100 |
Why?
|
| Malaria, Falciparum | 1 | 2021 | 1076 | 0.100 |
Why?
|
| Research | 3 | 2017 | 1977 | 0.100 |
Why?
|
| Ultrafiltration | 1 | 2012 | 49 | 0.100 |
Why?
|
| Protease Inhibitors | 3 | 2012 | 753 | 0.100 |
Why?
|
| Monocytes | 3 | 2019 | 2565 | 0.100 |
Why?
|
| Entropy | 2 | 2011 | 210 | 0.100 |
Why?
|
| Genetic Variation | 6 | 2019 | 6561 | 0.100 |
Why?
|
| Virion | 1 | 2014 | 422 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2019 | 1333 | 0.100 |
Why?
|
| Microfluidics | 2 | 2015 | 651 | 0.100 |
Why?
|
| Immunophenotyping | 6 | 2015 | 1864 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 3 | 2016 | 1454 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 3 | 2023 | 5493 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2016 | 600 | 0.100 |
Why?
|
| Africa South of the Sahara | 3 | 2020 | 745 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2018 | 1754 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 2 | 2020 | 901 | 0.100 |
Why?
|
| Genome, Viral | 4 | 2018 | 665 | 0.100 |
Why?
|
| Neoplasms | 2 | 2018 | 22131 | 0.100 |
Why?
|
| Microchip Analytical Procedures | 1 | 2011 | 29 | 0.100 |
Why?
|
| Blood Component Removal | 1 | 2012 | 132 | 0.100 |
Why?
|
| Amides | 2 | 2011 | 449 | 0.090 |
Why?
|
| Deoxycytidine | 3 | 2014 | 878 | 0.090 |
Why?
|
| Antibodies, Blocking | 1 | 2012 | 243 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 933 | 0.090 |
Why?
|
| Radioactive Waste | 2 | 1990 | 8 | 0.090 |
Why?
|
| Streptococcus | 1 | 1991 | 197 | 0.090 |
Why?
|
| Prospective Studies | 13 | 2023 | 54364 | 0.090 |
Why?
|
| Goals | 1 | 2016 | 708 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 10754 | 0.090 |
Why?
|
| Patient Participation | 1 | 2020 | 1443 | 0.090 |
Why?
|
| Virus Attachment | 1 | 2010 | 55 | 0.090 |
Why?
|
| Alanine | 2 | 2024 | 609 | 0.090 |
Why?
|
| Disease Progression | 7 | 2014 | 13495 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 827 | 0.090 |
Why?
|
| Blood | 1 | 2013 | 596 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2013 | 2659 | 0.090 |
Why?
|
| Leukemia Virus, Murine | 1 | 2010 | 94 | 0.090 |
Why?
|
| United States | 15 | 2021 | 72292 | 0.090 |
Why?
|
| Rifampin | 1 | 2012 | 339 | 0.090 |
Why?
|
| Retroviridae Infections | 1 | 2010 | 147 | 0.090 |
Why?
|
| Waste Products | 1 | 1990 | 12 | 0.090 |
Why?
|
| Medical Waste | 1 | 1990 | 16 | 0.090 |
Why?
|
| Refuse Disposal | 1 | 1990 | 31 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 235 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1810 | 0.090 |
Why?
|
| World Health Organization | 3 | 2013 | 1321 | 0.090 |
Why?
|
| Cytokines | 3 | 2021 | 7373 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2011 | 1989 | 0.080 |
Why?
|
| Adenoviridae | 2 | 2011 | 1084 | 0.080 |
Why?
|
| HIV Antigens | 6 | 2014 | 325 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2012 | 748 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4269 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 317 | 0.080 |
Why?
|
| Vaccination | 3 | 2011 | 3370 | 0.080 |
Why?
|
| Sterilization | 1 | 1990 | 132 | 0.080 |
Why?
|
| Optical Devices | 1 | 2009 | 35 | 0.080 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2010 | 215 | 0.080 |
Why?
|
| Protozoan Infections | 1 | 1988 | 38 | 0.080 |
Why?
|
| Viruses | 1 | 2012 | 374 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2013 | 1081 | 0.080 |
Why?
|
| Remission Induction | 1 | 2014 | 2391 | 0.080 |
Why?
|
| Myositis | 1 | 1991 | 269 | 0.080 |
Why?
|
| Luciferases | 1 | 2010 | 712 | 0.080 |
Why?
|
| Quality of Life | 3 | 2024 | 13359 | 0.080 |
Why?
|
| Gene Dosage | 1 | 2012 | 1217 | 0.080 |
Why?
|
| Antigens, Viral | 4 | 2020 | 988 | 0.070 |
Why?
|
| Tetanus Toxoid | 2 | 2000 | 188 | 0.070 |
Why?
|
| Quantum Dots | 1 | 2009 | 167 | 0.070 |
Why?
|
| Child | 16 | 2024 | 80089 | 0.070 |
Why?
|
| Glycerolphosphate Dehydrogenase | 2 | 1985 | 37 | 0.070 |
Why?
|
| Reassortant Viruses | 1 | 2007 | 36 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 435 | 0.070 |
Why?
|
| Disinfection | 1 | 1990 | 207 | 0.070 |
Why?
|
| Government Programs | 1 | 2010 | 278 | 0.070 |
Why?
|
| Genitalia, Female | 1 | 1988 | 147 | 0.070 |
Why?
|
| Area Under Curve | 3 | 2010 | 1635 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2004 | 960 | 0.070 |
Why?
|
| Case Management | 1 | 2009 | 272 | 0.070 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 15498 | 0.070 |
Why?
|
| HIV Core Protein p24 | 3 | 2014 | 245 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 1988 | 192 | 0.070 |
Why?
|
| Young Adult | 15 | 2020 | 59191 | 0.070 |
Why?
|
| Neutrophils | 1 | 2000 | 3763 | 0.070 |
Why?
|
| AIDS Dementia Complex | 1 | 2008 | 153 | 0.070 |
Why?
|
| Adolescent | 19 | 2020 | 88247 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2022 | 965 | 0.070 |
Why?
|
| Drug Combinations | 3 | 2020 | 2048 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 1378 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2009 | 2178 | 0.070 |
Why?
|
| Simian immunodeficiency virus | 1 | 2011 | 810 | 0.070 |
Why?
|
| Decision Making | 1 | 2020 | 3919 | 0.070 |
Why?
|
| Pregnancy | 11 | 2020 | 29869 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2010 | 1525 | 0.070 |
Why?
|
| Half-Life | 3 | 2017 | 650 | 0.070 |
Why?
|
| Purine Nucleosides | 1 | 2006 | 30 | 0.070 |
Why?
|
| Acidosis, Lactic | 1 | 2007 | 146 | 0.070 |
Why?
|
| Heterozygote | 1 | 2013 | 2780 | 0.070 |
Why?
|
| Dioxolanes | 1 | 2006 | 23 | 0.070 |
Why?
|
| Risk | 4 | 2018 | 9603 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2011 | 857 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2009 | 991 | 0.060 |
Why?
|
| Cells, Cultured | 8 | 2018 | 18937 | 0.060 |
Why?
|
| Alleles | 4 | 2016 | 6861 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2447 | 0.060 |
Why?
|
| Virus Activation | 2 | 2018 | 319 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 3394 | 0.060 |
Why?
|
| Laboratories | 4 | 2003 | 458 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6473 | 0.060 |
Why?
|
| Escherichia coli | 5 | 2001 | 4210 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2005 | 109 | 0.060 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 2 | 2017 | 63 | 0.060 |
Why?
|
| Plasmids | 1 | 2010 | 2265 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1250 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 12448 | 0.060 |
Why?
|
| Kinetics | 3 | 2011 | 6370 | 0.060 |
Why?
|
| Candida | 3 | 2009 | 171 | 0.060 |
Why?
|
| Human T-lymphotropic virus 2 | 2 | 1996 | 10 | 0.060 |
Why?
|
| Infant | 9 | 2023 | 36157 | 0.060 |
Why?
|
| Pyrimidinones | 1 | 2007 | 385 | 0.060 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 1994 | 151 | 0.060 |
Why?
|
| Deltaretrovirus Antigens | 2 | 1995 | 3 | 0.060 |
Why?
|
| C-Reactive Protein | 2 | 2020 | 3820 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 244 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2002 | 1349 | 0.060 |
Why?
|
| Vaccines, Synthetic | 2 | 2012 | 612 | 0.060 |
Why?
|
| Selection, Genetic | 1 | 2009 | 868 | 0.060 |
Why?
|
| Drug Resistance | 4 | 2000 | 1594 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2007 | 429 | 0.060 |
Why?
|
| Prevalence | 4 | 2020 | 15702 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 1394 | 0.060 |
Why?
|
| DNA | 3 | 2024 | 7196 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3567 | 0.060 |
Why?
|
| Virulence | 1 | 2008 | 1299 | 0.060 |
Why?
|
| Regression Analysis | 4 | 2007 | 6339 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2003 | 36 | 0.060 |
Why?
|
| Operon | 2 | 1985 | 372 | 0.060 |
Why?
|
| Counseling | 1 | 2012 | 1538 | 0.060 |
Why?
|
| Nucleosides | 1 | 2004 | 131 | 0.060 |
Why?
|
| Mutagenesis | 2 | 2004 | 1230 | 0.050 |
Why?
|
| Equipment Design | 4 | 2015 | 3501 | 0.050 |
Why?
|
| Equipment Failure Analysis | 3 | 2012 | 843 | 0.050 |
Why?
|
| Aging | 2 | 2015 | 8700 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 3031 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2009 | 1070 | 0.050 |
Why?
|
| Linear Models | 2 | 2010 | 5866 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 3051 | 0.050 |
Why?
|
| Prisoners | 1 | 2006 | 314 | 0.050 |
Why?
|
| Uganda | 1 | 2008 | 1332 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2713 | 0.050 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 994 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2007 | 3088 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2004 | 263 | 0.050 |
Why?
|
| Electroporation | 1 | 2023 | 233 | 0.050 |
Why?
|
| Child, Preschool | 8 | 2022 | 42193 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2006 | 4172 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2023 | 555 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 7390 | 0.050 |
Why?
|
| Clone Cells | 2 | 2002 | 1657 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2001 | 317 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2001 | 2601 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2004 | 470 | 0.050 |
Why?
|
| Social Justice | 1 | 2006 | 478 | 0.050 |
Why?
|
| Genes, Viral | 3 | 1999 | 649 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2002 | 149 | 0.050 |
Why?
|
| Antigens, CD | 3 | 2015 | 3998 | 0.050 |
Why?
|
| Mothers | 2 | 2024 | 2194 | 0.050 |
Why?
|
| Sex Factors | 2 | 2012 | 10549 | 0.050 |
Why?
|
| Genes, nef | 1 | 2001 | 52 | 0.050 |
Why?
|
| Furans | 2 | 2001 | 202 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2006 | 610 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2013 | 1957 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2003 | 2878 | 0.050 |
Why?
|
| Reference Standards | 2 | 2015 | 1003 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2008 | 1027 | 0.050 |
Why?
|
| Carbamates | 2 | 2001 | 191 | 0.050 |
Why?
|
| Immunotherapy | 3 | 2012 | 4642 | 0.050 |
Why?
|
| Bayes Theorem | 4 | 2016 | 2327 | 0.050 |
Why?
|
| Immune System | 2 | 2012 | 791 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 231 | 0.050 |
Why?
|
| Interferon-gamma | 3 | 2010 | 3145 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2005 | 709 | 0.050 |
Why?
|
| Genes | 2 | 1984 | 1823 | 0.040 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2001 | 168 | 0.040 |
Why?
|
| Lipodystrophy | 1 | 2001 | 145 | 0.040 |
Why?
|
| Adipose Tissue | 2 | 2003 | 3310 | 0.040 |
Why?
|
| Sulfuric Acid Esters | 1 | 2020 | 32 | 0.040 |
Why?
|
| Integrases | 1 | 2023 | 518 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2021 | 194 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 1550 | 0.040 |
Why?
|
| Inflammation | 4 | 2023 | 10759 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2021 | 696 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 1984 | 1073 | 0.040 |
Why?
|
| Complement Pathway, Classical | 1 | 1999 | 91 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 1375 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2000 | 134 | 0.040 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2000 | 72 | 0.040 |
Why?
|
| Gene Products, pol | 1 | 1999 | 43 | 0.040 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 846 | 0.040 |
Why?
|
| Hypersensitivity, Delayed | 4 | 2003 | 490 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 3 | 1986 | 145 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12043 | 0.040 |
Why?
|
| Confidentiality | 1 | 2003 | 608 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2002 | 1797 | 0.040 |
Why?
|
| Logistic Models | 5 | 2013 | 13248 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 1988 | 0.040 |
Why?
|
| Lenses | 2 | 2009 | 42 | 0.040 |
Why?
|
| AIDS Serodiagnosis | 1 | 2020 | 219 | 0.040 |
Why?
|
| Salmonella typhimurium | 1 | 2001 | 347 | 0.040 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1999 | 76 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 799 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 2013 | 0.040 |
Why?
|
| Neuropsychology | 1 | 2019 | 107 | 0.040 |
Why?
|
| Fluorescence | 2 | 2013 | 756 | 0.040 |
Why?
|
| Species Specificity | 4 | 2014 | 2410 | 0.040 |
Why?
|
| Defective Viruses | 1 | 2018 | 89 | 0.040 |
Why?
|
| Hospitals | 2 | 2022 | 3879 | 0.040 |
Why?
|
| Demography | 1 | 2023 | 1643 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 593 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2024 | 2929 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 254 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2024 | 1182 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 583 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2003 | 701 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2003 | 891 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1998 | 364 | 0.040 |
Why?
|
| Thymus Gland | 2 | 2000 | 1243 | 0.040 |
Why?
|
| Immunologic Memory | 2 | 2001 | 1355 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2001 | 860 | 0.040 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1998 | 507 | 0.040 |
Why?
|
| Health Resources | 1 | 2004 | 934 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2003 | 778 | 0.040 |
Why?
|
| Risk Factors | 7 | 2020 | 74128 | 0.040 |
Why?
|
| Saquinavir | 1 | 1997 | 29 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 441 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2003 | 1436 | 0.040 |
Why?
|
| Body Composition | 5 | 2007 | 2426 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2024 | 1242 | 0.040 |
Why?
|
| Algorithms | 5 | 2020 | 14024 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 1984 | 1866 | 0.040 |
Why?
|
| Intention | 1 | 2020 | 346 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 39062 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 1602 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 1748 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 3149 | 0.030 |
Why?
|
| Sulfonic Acids | 1 | 1997 | 103 | 0.030 |
Why?
|
| Paper | 1 | 2017 | 84 | 0.030 |
Why?
|
| Glutathione | 1 | 2019 | 582 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 1996 | 165 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2020 | 23974 | 0.030 |
Why?
|
| Position-Specific Scoring Matrices | 1 | 2016 | 11 | 0.030 |
Why?
|
| Body Weight | 2 | 2024 | 4615 | 0.030 |
Why?
|
| Membrane Glycoproteins | 3 | 2011 | 3688 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2004 | 2764 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 1999 | 734 | 0.030 |
Why?
|
| Streptokinase | 1 | 1996 | 186 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2003 | 1742 | 0.030 |
Why?
|
| Aged | 14 | 2020 | 169092 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2016 | 326 | 0.030 |
Why?
|
| Graphite | 1 | 2017 | 78 | 0.030 |
Why?
|
| DNA Ligases | 1 | 1996 | 82 | 0.030 |
Why?
|
| Glutamine | 1 | 2019 | 576 | 0.030 |
Why?
|
| Trifluridine | 1 | 1996 | 28 | 0.030 |
Why?
|
| Silver | 1 | 2017 | 117 | 0.030 |
Why?
|
| Zalcitabine | 1 | 1995 | 43 | 0.030 |
Why?
|
| Solubility | 1 | 2018 | 1089 | 0.030 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1995 | 74 | 0.030 |
Why?
|
| Microscopy | 1 | 2021 | 905 | 0.030 |
Why?
|
| Public Health | 2 | 2020 | 2671 | 0.030 |
Why?
|
| Adipocytes | 1 | 2003 | 1187 | 0.030 |
Why?
|
| Protein Conformation | 2 | 2016 | 3965 | 0.030 |
Why?
|
| Age Factors | 1 | 2012 | 18381 | 0.030 |
Why?
|
| Neonatal Screening | 1 | 2020 | 597 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1650 | 0.030 |
Why?
|
| Giant Cells | 1 | 1996 | 188 | 0.030 |
Why?
|
| Benzoxazoles | 1 | 1996 | 90 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1997 | 352 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2023 | 1985 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2021 | 1670 | 0.030 |
Why?
|
| Prognosis | 6 | 2010 | 29601 | 0.030 |
Why?
|
| Forecasting | 1 | 2024 | 2924 | 0.030 |
Why?
|
| Glucose Tolerance Test | 3 | 2003 | 1178 | 0.030 |
Why?
|
| Plasmacytoma | 1 | 1995 | 171 | 0.030 |
Why?
|
| Platelet Count | 1 | 1998 | 780 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2000 | 4110 | 0.030 |
Why?
|
| Leptin | 1 | 2003 | 1595 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 330 | 0.030 |
Why?
|
| Retrospective Studies | 10 | 2014 | 80583 | 0.030 |
Why?
|
| Disaster Planning | 1 | 2020 | 557 | 0.030 |
Why?
|
| Therapeutic Equivalency | 1 | 2014 | 134 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 2546 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2015 | 214 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 273 | 0.030 |
Why?
|
| Mycoses | 1 | 1998 | 386 | 0.030 |
Why?
|
| Health Services Accessibility | 3 | 2013 | 5430 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 825 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 786 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 659 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2016 | 426 | 0.030 |
Why?
|
| Recurrence | 2 | 2017 | 8426 | 0.030 |
Why?
|
| Drug Design | 1 | 1999 | 1045 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 2016 | 725 | 0.030 |
Why?
|
| Cell Division | 2 | 1999 | 4457 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2018 | 1900 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8516 | 0.030 |
Why?
|
| Cell Fusion | 1 | 1994 | 294 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2015 | 601 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17878 | 0.030 |
Why?
|
| Herpesviridae Infections | 1 | 2015 | 269 | 0.030 |
Why?
|
| Blood Preservation | 1 | 1994 | 169 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2019 | 1175 | 0.030 |
Why?
|
| Transfection | 1 | 2001 | 5765 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 714 | 0.030 |
Why?
|
| Social Stigma | 1 | 2020 | 769 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2016 | 5433 | 0.030 |
Why?
|
| Proteome | 1 | 2023 | 1857 | 0.030 |
Why?
|
| Massachusetts | 2 | 2020 | 8835 | 0.030 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 1993 | 17 | 0.030 |
Why?
|
| Dielectric Spectroscopy | 1 | 2013 | 27 | 0.030 |
Why?
|
| Suppuration | 1 | 1992 | 60 | 0.030 |
Why?
|
| Polystyrenes | 1 | 2013 | 104 | 0.030 |
Why?
|
| Telomere | 1 | 1999 | 942 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2019 | 1140 | 0.030 |
Why?
|
| Cell Death | 1 | 2018 | 1677 | 0.030 |
Why?
|
| Health Personnel | 1 | 2006 | 3333 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1996 | 465 | 0.030 |
Why?
|
| Hospitalization | 3 | 2020 | 10708 | 0.030 |
Why?
|
| Cross-Sectional Studies | 7 | 2012 | 26065 | 0.030 |
Why?
|
| Catalase | 1 | 1992 | 218 | 0.030 |
Why?
|
| Anaerobiosis | 4 | 1986 | 139 | 0.020 |
Why?
|
| HLA Antigens | 2 | 2011 | 1327 | 0.020 |
Why?
|
| Safety | 3 | 2005 | 1149 | 0.020 |
Why?
|
| Histones | 1 | 2022 | 2577 | 0.020 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2012 | 99 | 0.020 |
Why?
|
| ROC Curve | 2 | 2013 | 3575 | 0.020 |
Why?
|
| Placenta | 1 | 2001 | 1709 | 0.020 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2011 | 62 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2016 | 800 | 0.020 |
Why?
|
| Caregivers | 1 | 2024 | 2241 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1992 | 142 | 0.020 |
Why?
|
| Administration, Intravaginal | 1 | 2011 | 149 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 2021 | 1740 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2017 | 1470 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2630 | 0.020 |
Why?
|
| Pandemics | 2 | 2021 | 8652 | 0.020 |
Why?
|
| Pyridines | 3 | 2014 | 2875 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1992 | 302 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1996 | 1141 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4226 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3205 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2495 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3074 | 0.020 |
Why?
|
| Lipids | 2 | 2015 | 3332 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 140 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2014 | 1490 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2001 | 2674 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
| Immunoconjugates | 1 | 2018 | 951 | 0.020 |
Why?
|
| Volatilization | 1 | 1990 | 77 | 0.020 |
Why?
|
| Steam | 1 | 1990 | 29 | 0.020 |
Why?
|
| Rural Population | 1 | 2020 | 2277 | 0.020 |
Why?
|
| Health Policy | 2 | 2017 | 2682 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2001 | 2722 | 0.020 |
Why?
|
| Cell Separation | 1 | 2015 | 1718 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 1509 | 0.020 |
Why?
|
| International Cooperation | 1 | 2016 | 1422 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 489 | 0.020 |
Why?
|
| Outpatients | 1 | 1998 | 1596 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1997 | 1780 | 0.020 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 4242 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2020 | 3017 | 0.020 |
Why?
|
| Cryopreservation | 1 | 1994 | 728 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 14599 | 0.020 |
Why?
|
| Environment | 1 | 2015 | 1123 | 0.020 |
Why?
|
| Mycobacterium avium Complex | 1 | 2009 | 60 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2016 | 3601 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2014 | 1185 | 0.020 |
Why?
|
| Surface Properties | 1 | 2012 | 1162 | 0.020 |
Why?
|
| Gene Amplification | 3 | 2003 | 1087 | 0.020 |
Why?
|
| Tropism | 1 | 2008 | 44 | 0.020 |
Why?
|
| Arginine | 1 | 2012 | 933 | 0.020 |
Why?
|
| Software | 2 | 2018 | 4432 | 0.020 |
Why?
|
| Radioisotopes | 1 | 1990 | 499 | 0.020 |
Why?
|
| Temperature | 1 | 2015 | 2224 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 1999 | 1813 | 0.020 |
Why?
|
| Homosexuality, Male | 1 | 2016 | 1333 | 0.020 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2008 | 59 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2010 | 532 | 0.020 |
Why?
|
| Computational Biology | 1 | 2000 | 3509 | 0.020 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 15250 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2019 | 3115 | 0.020 |
Why?
|
| Proteins | 1 | 2003 | 6030 | 0.020 |
Why?
|
| Lysine | 1 | 2012 | 993 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2016 | 2025 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1994 | 1300 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 3793 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 1988 | 176 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 491 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 934 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2003 | 4785 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 15908 | 0.020 |
Why?
|
| Libya | 1 | 2006 | 9 | 0.020 |
Why?
|
| Systems Integration | 1 | 2009 | 426 | 0.020 |
Why?
|
| Nanomedicine | 1 | 2010 | 289 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2000 | 10072 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2015 | 6390 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 2 | 1998 | 7403 | 0.020 |
Why?
|
| Lactates | 1 | 2007 | 404 | 0.020 |
Why?
|
| Tanzania | 1 | 2011 | 1390 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2011 | 706 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9313 | 0.020 |
Why?
|
| Jurisprudence | 1 | 2006 | 109 | 0.020 |
Why?
|
| Radiation Protection | 1 | 1990 | 424 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1993 | 831 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 1217 | 0.020 |
Why?
|
| Insulin Resistance | 3 | 2007 | 3954 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2020 | 2948 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 1061 | 0.020 |
Why?
|
| Health Services Administration | 1 | 2006 | 63 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 3026 | 0.020 |
Why?
|
| Vancomycin | 1 | 1988 | 503 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2011 | 2328 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2011 | 9644 | 0.020 |
Why?
|
| Kidney Diseases | 2 | 2008 | 2090 | 0.010 |
Why?
|
| Pyrones | 1 | 2004 | 35 | 0.010 |
Why?
|
| Infant, Premature | 1 | 1994 | 2107 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 1202 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2017 | 3599 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 21339 | 0.010 |
Why?
|
| Amino Acids | 1 | 2010 | 1718 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2011 | 1799 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 7583 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2713 | 0.010 |
Why?
|
| Cilia | 1 | 1988 | 492 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2016 | 3901 | 0.010 |
Why?
|
| Mathematics | 1 | 2005 | 707 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 982 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 2003 | 114 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 320 | 0.010 |
Why?
|
| Disease Management | 1 | 2014 | 2506 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 274 | 0.010 |
Why?
|
| Protein Binding | 1 | 2016 | 9345 | 0.010 |
Why?
|
| Cell Proliferation | 2 | 2010 | 10429 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 8998 | 0.010 |
Why?
|
| Cross Infection | 1 | 1993 | 1422 | 0.010 |
Why?
|
| Animals | 8 | 2011 | 168202 | 0.010 |
Why?
|
| Mice, SCID | 2 | 2000 | 2625 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1990 | 1438 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2013 | 2597 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2005 | 367 | 0.010 |
Why?
|
| Pulse Therapy, Drug | 1 | 2002 | 37 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2003 | 174 | 0.010 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 151 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 679 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15829 | 0.010 |
Why?
|
| Cross-Over Studies | 2 | 2001 | 2079 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2002 | 70 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2003 | 310 | 0.010 |
Why?
|
| Age Distribution | 1 | 2008 | 2872 | 0.010 |
Why?
|
| Organizations | 1 | 2003 | 171 | 0.010 |
Why?
|
| Sample Size | 1 | 2006 | 838 | 0.010 |
Why?
|
| Immunity | 1 | 2008 | 994 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 680 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2007 | 1139 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2011 | 3431 | 0.010 |
Why?
|
| Retinal Diseases | 1 | 1987 | 704 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1985 | 666 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 671 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 1186 | 0.010 |
Why?
|
| Probability | 1 | 2007 | 2475 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2011 | 3392 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1988 | 1265 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 3419 | 0.010 |
Why?
|
| Apoptosis | 3 | 2003 | 9476 | 0.010 |
Why?
|
| Organ Transplantation | 1 | 2010 | 1157 | 0.010 |
Why?
|
| Mumps virus | 1 | 2000 | 23 | 0.010 |
Why?
|
| Hepatitis A Vaccines | 1 | 2000 | 26 | 0.010 |
Why?
|
| Neurons | 1 | 2019 | 9436 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2000 | 116 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2004 | 529 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7805 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2008 | 1297 | 0.010 |
Why?
|
| Lac Operon | 1 | 1979 | 237 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 1999 | 38 | 0.010 |
Why?
|
| Acute Disease | 1 | 2010 | 7236 | 0.010 |
Why?
|
| North America | 1 | 2003 | 1273 | 0.010 |
Why?
|
| NAD+ Nucleosidase | 1 | 1999 | 43 | 0.010 |
Why?
|
| Brazil | 1 | 2003 | 1229 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 1317 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1999 | 851 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2000 | 1301 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1999 | 240 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 16968 | 0.010 |
Why?
|
| Sequence Analysis, Protein | 1 | 2000 | 261 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 1338 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 1550 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 1700 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 6223 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2004 | 1524 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1998 | 216 | 0.010 |
Why?
|
| Tomography | 1 | 2000 | 411 | 0.010 |
Why?
|
| Abdomen | 1 | 2003 | 1128 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 2003 | 1738 | 0.010 |
Why?
|
| Adiponectin | 1 | 2003 | 1107 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 2231 | 0.010 |
Why?
|
| Retroviridae | 1 | 1999 | 851 | 0.010 |
Why?
|
| Antipyrine | 1 | 1996 | 40 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1988 | 3672 | 0.010 |
Why?
|
| Hemagglutinins, Viral | 1 | 1995 | 66 | 0.010 |
Why?
|
| Bacterial Proteins | 2 | 1986 | 3842 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1999 | 908 | 0.010 |
Why?
|
| Acyclovir | 1 | 1996 | 267 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2003 | 12942 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13635 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3752 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1996 | 238 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2002 | 9310 | 0.010 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1995 | 158 | 0.010 |
Why?
|
| Nitrates | 2 | 1986 | 263 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1996 | 329 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 526 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1996 | 703 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 7512 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1624 | 0.010 |
Why?
|
| Pneumonia | 1 | 2005 | 2143 | 0.010 |
Why?
|
| Aerobiosis | 2 | 1986 | 100 | 0.010 |
Why?
|
| HTLV-II Antigens | 1 | 1992 | 1 | 0.010 |
Why?
|
| HTLV-II Antibodies | 1 | 1992 | 3 | 0.010 |
Why?
|
| HTLV-I Antigens | 1 | 1992 | 7 | 0.010 |
Why?
|
| Deltaretrovirus Antibodies | 1 | 1992 | 9 | 0.010 |
Why?
|
| Radioimmunoprecipitation Assay | 1 | 1992 | 16 | 0.010 |
Why?
|
| HTLV-I Antibodies | 1 | 1992 | 35 | 0.010 |
Why?
|
| Antigens | 1 | 1998 | 1441 | 0.010 |
Why?
|
| Immune Sera | 1 | 1992 | 605 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 12759 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12661 | 0.010 |
Why?
|
| Waste Disposal, Fluid | 1 | 1990 | 33 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1992 | 816 | 0.010 |
Why?
|
| Spleen | 1 | 1995 | 2286 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2003 | 5074 | 0.000 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 9526 | 0.000 |
Why?
|
| Mice | 3 | 2001 | 81368 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1992 | 2467 | 0.000 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2002 | 4010 | 0.000 |
Why?
|
| Sleep | 1 | 2003 | 4764 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 3730 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 4533 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1995 | 6188 | 0.000 |
Why?
|
| Succinates | 1 | 1986 | 81 | 0.000 |
Why?
|
| Suppression, Genetic | 1 | 1986 | 190 | 0.000 |
Why?
|
| Enzyme Induction | 1 | 1986 | 452 | 0.000 |
Why?
|
| Succinic Acid | 1 | 1986 | 86 | 0.000 |
Why?
|
| Rabbits | 1 | 1992 | 4770 | 0.000 |
Why?
|
| Epitopes | 1 | 1992 | 2501 | 0.000 |
Why?
|
| Diet | 1 | 2003 | 8049 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1998 | 4745 | 0.000 |
Why?
|
| Genes, Regulator | 1 | 1985 | 373 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 58919 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 20556 | 0.000 |
Why?
|
| beta-Galactosidase | 1 | 1979 | 574 | 0.000 |
Why?
|
| Gene Expression Regulation | 2 | 1986 | 11874 | 0.000 |
Why?
|
| Retina | 1 | 1987 | 2655 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1990 | 4483 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1987 | 11069 | 0.000 |
Why?
|